PhysEmp :: Medicine :: Medical Specialties :: Neurology (10)

All Neurology Jobs

Missouri Hospital Needs Inpatient Call Coverage Starting Next Year. :: Missouri :: CompHealth Inc
Job 0840799-0194 Requires: EEG About 9-12 patients per day 100% Inpatient We offer competitive pay that may include incentives and bonuses We coordinate and pay for your travel, housing, and transportation
Neurology - Epilepsy Temp to Perm Opportunity in Pennsylvania :: Pennsylvania :: CompHealth Inc
Job 0053655-0359 This is an excellent opportunity to join a well-established hospital employed practice. Beautiful and family friendly community, one of the nations lowest crime rates, diversified economic
Adult Neurologist Needed in the 4 Corners Region - NM :: New Mexico :: CompHealth Inc
Job 92138 Neurologist needed to join 2 in Existing Group Board Certified or Board Eligible Established Program - EMG, EEG, NCV, Botulinum injections for movement disorders, nerve blocks Join 2 in an

Archives of Neurology recent issues

Infectious Burden and Risk of Stroke: The Northern Manhattan Study [Original Contribution]
Elkind, M. S. V., Ramakrishnan, P., Moon, Y. P., Boden-Albala, B., Liu, K. M., Spitalnik, S. L., Rundek, T., Sacco, R. L., Paik, M. C.Objective  To determine the association between a composite measure of serological test results for common infections (Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus 1 and 2) and stroke risk in a prospective cohort study.Design  Prospective cohort followed up longitudinally for median 8 years.Setting  Northern Manhattan Study.Patients  Randomly selected stroke-free participants from a multiethnic urban community.Main Outcome Measure  Incident stroke and other vascular events.Results  All 5 infectious serological results were available from baseline samples in 1625 participants (mean [SD] age, 68.4 [10.1] years; 64.9% women). Cox proportional hazards models were used to estimate associations of each positive serological test result with stroke. Individual parameter estimates were then combined into a weighted index of infectious burden and used to calculate hazard ratios and confidence intervals for association with risk of stroke and other outcomes, adjusted for risk factors. Each individual infection was positively, though not significantly, associated with stroke risk after adjusting for other risk factors. The infectious burden index was associated with an increased risk of all strokes (adjusted hazard ratio per standard deviation, 1.39; 95% confidence interval, 1.02-1.90) after adjusting for demographics and risk factors. Results were similar after excluding those with coronary disease (adjusted hazard ratio, 1.50; 95% confidence interval, 1.05-2.13) and adjusting for inflammatory biomarkers.Conclusions  A quantitative weighted index of infectious burden was associated with risk of first stroke in this cohort. Future studies are needed to confirm these findings and to further define optimal measures of infectious burden as a stroke risk factor.Published online November 9, 2009 (doi:10.1001/archneurol.2009.271).
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease [Original Contribution]
Ascherio, A., LeWitt, P. A., Xu, K., Eberly, S., Watts, A., Matson, W. R., Marras, C., Kieburtz, K., Rudolph, A., Bogdanov, M. B., Schwid, S. R., Tennis, M., Tanner, C. M., Beal, M. F., Lang, A. E., Oakes, D., Fahn, S., Shoulson, I., Schwarzschild, M. A., for the Parkinson Study Group DATATOP InvestigatorsBackground  The risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant.Objective  To determine whether serum and cerebrospinal fluid concentrations of urate predict clinical progression in patients with PD.Design, Setting, and Participants  Eight hundred subjects with early PD enrolled in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. The pretreatment urate concentration was measured in serum for 774 subjects and in cerebrospinal fluid for 713 subjects.Main Outcome Measures  Treatment-, age-, and sex-adjusted hazard ratios (HRs) for clinical disability requiring levodopa therapy, the prespecified primary end point of the original DATATOP trial.Results  The HR of progressing to the primary end point decreased with increasing serum urate concentrations (HR for highest vs lowest quintile = 0.64; 95% confidence interval [CI], 0.44-0.94; HR for a 1-SD increase = 0.82; 95% CI, 0.73-0.93). In analyses stratified by -tocopherol treatment (2000 IU/d), a decrease in the HR for the primary end point was seen only among subjects not treated with -tocopherol (HR for a 1-SD increase = 0.75; 95% CI, 0.62-0.89; vs HR for those treated = 0.90; 95% CI, 0.75-1.08). Results were similar for the rate of change in the Unified Parkinson's Disease Rating Scale score. Cerebrospinal fluid urate concentration was also inversely related to both the primary end point (HR for highest vs lowest quintile = 0.65; 95% CI, 0.44-0.96; HR for a 1-SD increase = 0.89; 95% CI, 0.79-1.02) and the rate of change in the Unified Parkinson's Disease Rating Scale score. As with serum urate concentration, these associations were present only among subjects not treated with -tocopherol.Conclusions  Higher serum and cerebrospinal fluid urate concentrations at baseline were associated with slower rates of clinical decline. The findings strengthen the link between urate concentration and PD and the rationale for considering central nervous system urate concentration elevation as a potential strategy to slow PD progression.Published online October 12, 2009 (doi:10.1001/archneurol.2009.247).
About This Journal [About This Journal]


Subscribe to Neurology RSS feed